HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
 Help
PRVB [NASD]
Provention Bio, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.64 Insider Own15.68% Shs Outstand63.40M Perf Week-19.29%
Market Cap209.37M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float53.21M Perf Month-14.25%
Income-104.00M PEG- EPS next Q-0.50 Inst Own39.10% Short Float7.54% Perf Quarter-53.14%
Sales2.00M P/S104.68 EPS this Y3.50% Inst Trans2.18% Short Ratio6.96 Perf Half Y-40.35%
Book/sh1.49 P/B2.30 EPS next Y42.30% ROA-69.40% Target Price16.21 Perf Year-58.82%
Cash/sh1.39 P/C2.46 EPS next 5Y- ROE-83.70% 52W Range3.40 - 9.35 Perf YTD-38.97%
Dividend- P/FCF- EPS past 5Y- ROI-103.50% 52W High-63.32% Beta2.62
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low0.88% ATR0.31
Employees82 Current Ratio3.40 Sales Q/Q- Oper. Margin- RSI (14)36.44 Volatility9.49% 7.94%
OptionableYes Debt/Eq0.00 EPS Q/Q33.50% Profit Margin- Rel Volume1.91 Prev Close4.00
ShortableYes LT Debt/Eq0.00 EarningsMay 05 BMO Payout- Avg Volume576.13K Price3.43
Recom1.90 SMA20-14.25% SMA50-19.81% SMA200-40.33% Volume1,101,321 Change-14.25%
Nov-23-21Upgrade SMBC Nikko Neutral → Outperform
Apr-09-21Reiterated SVB Leerink Outperform $26 → $16
Apr-09-21Downgrade RBC Capital Mkts Outperform → Sector Perform $27 → $25
Jun-16-20Reiterated H.C. Wainwright Buy $20 → $26
Jun-04-20Initiated RBC Capital Mkts Outperform $25
Jun-04-20Initiated Oppenheimer Outperform $29
Jan-24-20Initiated Cantor Fitzgerald Overweight $25
Jun-26-19Reiterated H.C. Wainwright Buy $8 → $20
Jun-10-19Initiated Chardan Capital Markets Buy $20
Feb-22-19Initiated SVB Leerink Outperform $6
Jun-30-22 04:01PM  
Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022
PR Newswire
Jun-23-22 10:58AM  
These 2 Penny Stocks Have Over 300% Upside on the Horizon, Says Oppenheimer
TipRanks
Jun-03-22 07:35AM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire +5.45%
07:30AM  
Provention Bio to Present at the Jefferies Global Healthcare Conference
PR Newswire
07:00AM  
Provention Bio Announces Update to Board of Directors
PR Newswire
May-30-22 07:12AM  
Is Provention Bio (NASDAQ:PRVB) In A Good Position To Invest In Growth?
Simply Wall St.
May-19-22 11:23AM  
2 High-Risk, High-Reward Stocks for Contrarian Investors
Motley Fool -6.24%
May-12-22 07:30AM  
Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year
PR Newswire +6.20%
May-05-22 08:25AM  
Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates
Zacks
07:00AM  
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
PR Newswire
May-03-22 07:30AM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire
Apr-29-22 01:29PM  
Investors one-year losses grow to 36% as the stock sheds US$56m this past week
Simply Wall St. -5.07%
Apr-28-22 07:30AM  
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
PR Newswire -5.31%
Apr-13-22 04:20AM  
AlzeCures Rights Issue is Registered and the Trading in Paid Subscription Shares Ceases
ACCESSWIRE +5.01%
Apr-04-22 04:05PM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire
Mar-28-22 03:27PM  
Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months
Benzinga
07:30AM  
Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
PR Newswire
Mar-04-22 04:05PM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire
Mar-03-22 07:30AM  
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
PR Newswire
Feb-26-22 07:14AM  
Is Provention Bio, Inc. (NASDAQ:PRVB) Popular Amongst Insiders?
Simply Wall St.
Feb-24-22 08:25AM  
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates
Zacks
07:00AM  
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
PR Newswire
Feb-22-22 01:59PM  
Provention Bio Resubmits Teplizumab Application In US For Type-1 Diabetes
Benzinga
07:30AM  
Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)
PR Newswire
Feb-17-22 04:05PM  
Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
PR Newswire
Feb-10-22 07:30AM  
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
PR Newswire
Feb-04-22 04:05PM  
Provention Bio Announces the Grant of Inducement Award
PR Newswire
Jan-31-22 04:13PM  
Why Provention Bio Stock Skyrocketed Today
Motley Fool +28.85%
Jan-28-22 12:04PM  
Why Provention Bio Stock Is Soaring Today
Motley Fool +22.35%
07:55AM  
FDA Gives Green Signal To Provention Bio's Delaying Diabetes Med Resubmission
Benzinga
Jan-27-22 04:05PM  
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA
PR Newswire -6.59%
Jan-21-22 06:57AM  
Provention Bio Starts Mid-Stage Lupus Trial; Data Expected In 2024
Benzinga -9.09%
Jan-20-22 04:05PM  
Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)
PR Newswire
Jan-07-22 07:30AM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire
Jan-06-22 07:30AM  
Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference
PR Newswire
Dec-20-21 07:34AM  
Provention Bio Announces Leadership Team Expansion
PR Newswire
Dec-02-21 07:30AM  
Provention Bio Announces the Grant of Inducement Awards
PR Newswire
Nov-29-21 08:02AM  
Will Provention Bio (NASDAQ:PRVB) Spend Its Cash Wisely?
Simply Wall St. -6.55%
Nov-25-21 10:00AM  
Wall Street Analysts Predict a 167% Upside in Provention Bio, Inc. (PRVB): Here's What You Should Know
Zacks
Nov-22-21 07:30AM  
Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway
PR Newswire +15.06%
Nov-17-21 07:30AM  
Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development
PR Newswire
Nov-09-21 12:00PM  
Provention Bio, Inc. (PRVB) Upgraded to Buy: What Does It Mean for the Stock?
Zacks
10:38AM  
How Much Upside is Left in Provention Bio, Inc. (PRVB)? Wall Street Analysts Think 187%
Zacks
08:00AM  
Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month
PR Newswire
Nov-06-21 01:00PM  
Provention Bio, inc (PRVB) Q3 2021 Earnings Call Transcript
Motley Fool
Nov-05-21 04:30PM  
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development
PR Newswire +6.21%
Nov-04-21 08:35AM  
Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates
Zacks
07:05AM  
Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer
PR Newswire
07:00AM  
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
PR Newswire
Oct-28-21 07:30AM  
Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
PR Newswire
Oct-26-21 01:43PM  
Provention Bio Reveals Early Data For Coxsackievirus B Vaccine Candidate
Benzinga
07:30AM  
Provention Bio Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
PR Newswire
Oct-21-21 09:32PM  
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio, Danimer Scientific, AcelRX, and Piedmont Lithium on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire
Sep-23-21 07:30AM  
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
PR Newswire
Sep-16-21 07:30AM  
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
PR Newswire
Sep-13-21 07:30AM  
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License Application (BLA) Resubmission
PR Newswire
Sep-10-21 12:19PM  
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential
InvestorPlace
Aug-30-21 10:34AM  
What Kind Of Investors Own Most Of Provention Bio, Inc. (NASDAQ:PRVB)?
Simply Wall St.
Aug-09-21 08:37PM  
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Provention Bio and Ontrak on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire -5.07%
Aug-06-21 07:00PM  
Provention Bio, inc (PRVB) Q2 2021 Earnings Call Transcript
Motley Fool
02:04PM  
Lifshitz Law Firm, P.C. Announces Investigations of ContextLogic, Inc. (NasdaqGS: WISH), Provention Bio, Inc. (NasdaqGS: PRVB), Ubiquiti Inc. (NYSE: UI), and Virgin Galactic holdings, Inc. (NYSE: SPCE)
GlobeNewswire
Aug-05-21 08:45AM  
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
Zacks +9.63%
07:00AM  
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
PR Newswire
Jul-29-21 07:00AM  
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
PR Newswire
Jul-20-21 02:20PM  
CLASS ACTION UPDATE for PRVB, FREQ and YMM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
ACCESSWIRE
01:35PM  
FINAL DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
10:40AM  
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PRVB, WPG and RKT
ACCESSWIRE
10:03AM  
PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
Newsfile
09:36AM  
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Newsfile
Jul-19-21 03:51PM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRVB, OCGN and DKNG
ACCESSWIRE
03:00PM  
Last Few Hours to Actively Participate in Provention Bio, Inc. (PRVB) Class Action - Bronstein, Gewirtz & Grossman, LLC
GlobeNewswire
02:30PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
ACCESSWIRE
12:21PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
Newsfile
10:40AM  
DEADLINE ALERT for UI, PRVB, and WPG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
GlobeNewswire
10:15AM  
CLASS ACTION UPDATE for PRVB, WPG and RCAR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
ACCESSWIRE
10:00AM  
PRVB TUESDAY DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 Deadline in Securities Class Action - PRVB
Newsfile
10:00AM  
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021
Business Wire
09:00AM  
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Newsfile
05:40AM  
SHAREHOLDER ALERT: SRAC PRVB DIDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
ACCESSWIRE
12:50AM  
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
Jul-18-21 11:49AM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
Newsfile
09:30AM  
FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action PRVB
GlobeNewswire
09:00AM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - PRVB
PR Newswire
Jul-16-21 07:30PM  
FINAL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - PRVB
PR Newswire
03:53PM  
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - (PRVB)
Newsfile
02:10PM  
FINAL DEADLINE IMMINENT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
01:05PM  
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
Newsfile
11:35AM  
PRVB Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: July 20, 2021
ACCESSWIRE
11:25AM  
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
Business Wire
10:35AM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRVB, BZ and QFIN
ACCESSWIRE
10:11AM  
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Newsfile
06:52AM  
Is Provention Bio a Bad News Buy?
Motley Fool
Jul-15-21 07:37PM  
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Behalf of Provention Bio, Inc. Limited Shareholders
Newsfile
06:05PM  
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of Class Action Lawsuit and Upcoming Deadline PRVB
GlobeNewswire
04:01PM  
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 20, 2021 - PRVB
Newsfile
02:30PM  
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
ACCESSWIRE
12:30PM  
LAWSUITS FILED AGAINST PRVB, ATHA and QFIN - Jakubowitz Law Pursues Shareholders Claims
ACCESSWIRE
12:00PM  
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
PR Newswire
11:00AM  
DEADLINE ALERT for PRVB, WPG, SPCE, OCGN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
GlobeNewswire
10:30AM  
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRVB, HMPT and RKT
ACCESSWIRE
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ramos EleanorChief Medical OfficerDec 03Buy6.495,20133,76570,000Dec 06 09:28 PM
Palmer AshleighDirector and CEONov 30Buy6.663,75024,9902,570,050Dec 01 09:21 PM
Leon FranciscoChief Scientific OfficerNov 24Buy7.245,55040,1882,573,000Nov 29 05:15 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do Not Sell My Data • Privacy Settings
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2022 FINVIZ.com. All Rights Reserved.